ArticleBMC neurology2026
Analysis of risk factors for adverse outcomes and development of a predictive model in patients with acute mild ischemic stroke following intravenous thrombolytic therapy with rt-PA.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo identify risk factors associated with early unfavorable outcomes in patients with mild ischemic stroke (MIS) treated with intravenous recombinant tissue plasminogen activator (rt-PA), develop a prognostic prediction model, and validate its performance externally using multi-center cohort data.
methodsThis study retrospectively enrolled 231 patients with MIS who received intravenous thrombolysis with rt-PA at the Second Affiliated Hospital of Fujian Medical University, Jinjiang Hospital, and Anxi County Hospital between January 2015 and September 2023 to form the training cohort. Patients were classified into favorable prognosis (mRS 0–1) and unfavorable prognosis (mRS 2–6) groups according to their mRS scores at discharge. Independent predictors were identified through univariate and multivariate logistic regression analyses, and a predictive nomogram model was developed based on these variables. Subsequently, an independent validation cohort comprising 63 MIS patients treated with rt-PA intravenous thrombolysis at Longyan City First Hospital during the same time period was used for external validation. Model performance was comprehensively assessed in terms of discrimination, calibration, and clinical utility using receiver operating characteristic (ROC) curve analysis, calibration plot, and decision curve analysis (DCA).
resultsMultivariate logistic regression analysis identified baseline NIHSS score (OR = 1.650), age (OR = 1.056), early neurological deterioration (END) (OR = 25.242), and anterior circulation infarction (OR = 2.468) as independent predictors of unfavorable prognosis. A nomogram model was subsequently developed based on these variables, demonstrating strong predictive performance in the training cohort with an area under the receiver operating characteristic curve (AUC) of 0.828. In the external validation cohort, the model maintained excellent discrimination, achieving an AUC of 0.827, with a sensitivity of 87.5%, specificity of 72.3%, and a negative predictive value of 94.4%. Calibration plots revealed good agreement between predicted and observed probabilities of unfavorable outcomes. Decision curve analysis further demonstrated that the model provides substantial clinical net benefit across a broad range of threshold probabilities.
conclusionsAge, baseline NIHSS score, END, and anterior circulation stroke are independent predictors of unfavorable prognosis in patients with MIS following intravenous thrombolysis with rt-PA. The predictive nomogram model developed from these variables demonstrated excellent accuracy, generalizability, and clinical utility after external validation, supporting the identification of high-risk individuals and aiding clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.